![Donald McCaffrey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: 1 Mio $ am 31.05.2026
Mr. Donald J.
McCaffrey is a Chairman, President & Chief Executive Officer at Zenith Capital Corp.
(Alberta) and a Chairman, President, CEO & Secretary at Resverlogix Corp.
Mr. McCaffrey also served on the board at Stem Cell Therapeutics Corp.
and ProMIS Neurosciences, Inc.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ZENITH CAPITAL CORP. 4,4 % | 31.03.2026 | 7.027.513 ( 4,4 % ) | 702 751 $ | 31.01.2026 |
RESVERLOGIX CORP. 1,53 % | 02.01.2026 | 5.263.266 ( 1,53 % ) | 384 218 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| RESVERLOGIX CORP. | Vorstandsvorsitzender | 25.04.2003 |
| ZENITH CAPITAL CORP. | Vorstandsvorsitzender | 10.04.2013 |
| Unternehmen | Position | Ende |
|---|---|---|
| TRILLIUM THERAPEUTICS | Direktor/Vorstandsmitglied | 27.03.2006 |
| PROMIS NEUROSCIENCES, INC. | Direktor/Vorstandsmitglied | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Resverlogix Corp.
 Resverlogix Corp. Pharmaceuticals: MajorHealth Technology Engages in the research and development of novel biopharmaceuticals for the treatment of grievous diseases | Health Technology |
Trillium Therapeutics, Inc.
 Trillium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures medicines & therapies for cancer | Health Technology |
Zenith Capital Corp. (Alberta)
 Zenith Capital Corp. (Alberta) BiotechnologyHealth Technology Engages in the research and development of biopharmaceuticals | Health Technology |
ProMIS Neurosciences, Inc.
 ProMIS Neurosciences, Inc. BiotechnologyHealth Technology Discovers and develops precision medicine solutions for the treatment of neurodegenerative & misfolded protein diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
